Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Oxford Lane Capital Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Oxford Lane Capital Corp trades at $9.49 (market cap $905.21M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 10.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.89% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | OXLC | |
|---|---|---|
Market Cap | $9.39B | $905.21M |
Sector | Health | Financials |
52-Week High | $356.25 | $18.75 |
52-Week Low | $241.71 | $8.15 |
Enterprise Value | $9.14B | — |
Dividend Yield | — | 25.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
OXLC trades at $9.20, up 0.44% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock's valuation shows a low price-to-book ratio of 0.88, yet profitability metrics are deeply negative with an ROE of -39.16%. Recent earnings have consistently missed expectations, and the company has declared a series of $0.20 dividends through 2026. Cash flow from operations was negative $703.80M in 2025, offset by financing activities.
The outlook is clouded by severe fundamental deterioration, including a projected revenue collapse and net loss for 2026. While the high dividend yield and discounted P/B may attract some investors, the risks from unsustainable distributions, declining net asset value, and negative returns on equity warrant extreme caution. Analyst sentiment is mixed, reflecting the stock's high-risk, high-yield profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
